SARAH VILLANI: Open Payments
NPI 1770089435 · HIGHLANDS RANCH, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$608 in 22 payments from 10 companies in 2025. Trend: 2023 $864 · 2024 $874 · 2025 $608
Food & beverage: $608
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 7 | $203 |
| Janssen Biotech, Inc. | 4 | $98 |
| Genentech USA, Inc. | 3 | $69 |
| Novartis Pharmaceuticals Corporation | 1 | $67 |
| TAIHO ONCOLOGY, INC. | 2 | $39 |
| Gilead Sciences, Inc. | 1 | $33 |
| Stemline Therapeutics Inc. | 1 | $30 |
| GENZYME CORPORATION | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
| ABBVIE INC. | 1 | $19 |
Products named: Lenvima, KISQALI, RYBREVANT, LONSURF, TECVAYLI, Trodelvy, Orserdu, WAYRILZ.
Industry payments across CO — which companies pay providers there.
